Another great recognition for Immune-Onc Therapeutics ! I am immensely proud of our team for their commitment to making a difference in the lives of patients and I am grateful to the S.F. Business Times Multimedia for shining a spotlight on the vital role of women leaders in the life sciences industry.

RETWEET if you believe! 🌟🔁 Tag two people or donate $20 today! This #MyelomaAwarenessMonth and year-round, your donations fuel our mission. ✨ Donate now 👉 bit.ly/3IRhpXq

I’m excited to announce that Immune-Onc Therapeutics will present new data on IO-202 in #CMML at the #EHA2024 conference in Spain next month. If you plan to attend #EHA2024, please get in touch to say “Hello” and learn more about our work in blood cancer. I look forward to seeing you there!

I’m pleased to announce positive new data from our Phase 1b trial of IO-202 in #CMML. We look forward to sharing these data with the medical community at #EHA2024 and working with the FDA to discuss plans for a registrational study to bring this innovative medicine to patients.

Thank you John Carroll for writing about your journey as a cancer patient and for shedding light on Merkel cell carcinoma (MCC) and the perseverance of drug developers to get 3 new medicines approved that mobilize our immune system to fight this rare cancer. We have more to come!

Check this out from my good friend Dr Ruth Ann Crystal. She provides an informative and important advice. I also like the monoclonal antibody that prevents RSV infection, with its long half-life and long-lasting effects.

The induction of these anti–IFN-α autoantibodies was temporally linked to a decline in IFN-α itself, suggesting that elicitation of these autoantibodies may be a mechanism to temper inflammation in the respiratory mucosa.

New #JITC article: Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors bit.ly/3ZgH0SF Aung Naing

Our Phase 1 data on IO-108 was published in Journal for ImmunoTherapy of Cancer · Durable responses in advanced solid tumors · Promising monotherapy & combo results with pembrolizumab · Potential to overcome resistance to checkpoint inhibitors bit.ly/3ZgH0SF

Immune-Onc Therapeutics will present important updates on its Phase 1b data on IO-202 for CMML. Don’t miss the oral presentation at #ASH2024 on Monday!

Fantastic presentation of groundbreaking Phase 1b data on IO-202 for CMML at #ASH2024! ✔️ CR: 50% | ORR: 66.7% ✔️ High LILRB4 expression: CR: 83%; ORR: 100% ✔️ 40% bridged to transplant ✔️Additional clinical benefits

I am inspired by the dedication of our team and grateful for the patients and clinical investigators who made this progress possible. These results bring us closer to transforming care for #CMML patients who urgently need innovative therapies.

Thank you to Dr. Gabe Mannis for presenting our impressive data of IO-202 for #CMML at #ASH2024. It was wonderful to meet you and additional investigators including Dr. Daniel Pollyea and our supporter 伊藤佑愛 CSO Dr Lee Greenberger!

Congratulations to Liqun Luo. We are proud of your accomplishments and happy for you.

This is an important step for Immune-Onc Therapeutics and for patients with #HCC. We look forward to learning how IO-108 may add to existing therapies and provide more choices for #patients. I’m very grateful to our team, our partners at Roche, and clinical investigators leading this effort.

The publication of our IO-202 Phase 1 data in Blood Neoplasia marks an important moment for Immune-Onc Therapeutics and for patients with HMA-naïve #CMML and monocytic #AML, who urgently need better options. We are grateful to the patients, investigators, care teams and staff for this work.